The selected channel has been deleted from your list of favorites.

Our News on Newswise

Newswise: 672b8c286b3f0_TCT2024SharkTank5SocialLinkedin.jpg

Symbiosis Wins TCT 2024 Shark Tank Innovation Competition

The Cardiovascular Research Foundation® (CRF®) is pleased to announce that Symbiosis has won the TCT® 2024 Shark Tank Innovation Competition for its development of an adjustable transcatheter mitral valve replacement (TMVR) system. The...
6-Nov-2024 10:30 AM EST Add to Favorites

Randomized Trial Demonstrates Benefits of Large-bore Mechanical Thrombectomy Over Catheter-directed Thrombolysis for Treatment of Intermediate-risk Pulmonary Embolism

Findings from the first international randomized controlled trial to compare patient outcomes following treatment with large-bore mechanical thrombectomy (LBMT) versus catheter-directed thrombolysis (CDT) for intermediate-risk pulmonary embolism...
30-Oct-2024 12:00 PM EDT Add to Favorites

Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes

The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularization.
30-Oct-2024 11:55 AM EDT Add to Favorites

Orbital Atherectomy Prior to Coronary Stent Implantation Does Not Lead to Better Outcomes Compared to Conventional Balloon Angioplasty

Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in...
30-Oct-2024 11:05 AM EDT Add to Favorites

Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis Shows Limited Benefits

Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS). Findings were reported...
29-Oct-2024 11:50 AM EDT Add to Favorites

Early Intervention in Patients with Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis Falls Short of Expected Benefits

The EVOLVED trial found that early aortic valve intervention in patients with asymptomatic severe aortic stenosis (AS) and mid-wall myocardial fibrosis on magnetic resonance imaging did not reduce the incidence of the composite primary endpoint of...
29-Oct-2024 11:40 AM EDT Add to Favorites

Study Finds Early TAVR Can Be Beneficial for Patients with Asymptomatic Severe Aortic Stenosis

The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be both a safe and effective alternative to clinical...
29-Oct-2024 11:35 AM EDT Add to Favorites

CRF® Announces 2024 SET-10 Rankings

The Cardiovascular Research Foundation® (CRF®) is proud to unveil the 2024 SET-10 (Scientific Excellence Top 10), recognizing the academic and medical institutions making the most impactful contributions to interventional cardiovascular research...
23-Oct-2024 12:55 PM EDT Add to Favorites


See All News

Our Experts on Newswise

CRF to Hold Free Seminar on Living with Heart Failure for Patients and Caregivers

CRF will hold a free seminar, “Broken Hearts: Living with Heart Failure,” on Tuesday, June 6, 2017 for heart failure patients and caregivers at NewYork-Presbyterian Hospital. The seminar will focus on providing both patients and caregivers a...
9-May-2017 12:05 PM EDT

See All Experts

Our YouTube Videos

About

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

CRF works to identify, develop and promote the latest advancements in the treatment of heart and vascular disease. By covering all aspects of the research continuum, we’re able to accelerate the speed with which breakthrough therapies reach patients through doctors, improving survival rates and quality of life for patients worldwide.

CRF carries out its mission by pursuing three basic goals:

Innovate
The CRF Skirball Center for Innovation guides early ideas and innovations through comprehensive preclinical research programs to introduce practical clinical therapies to patients.

Investigate
The CRF Clinical Trials Center plans and executes clinical investigations from first-in-man studies to large, multicenter, international trials and provides expert, independent qualitative and quantitative analyses of clinical and imaging data.

Educate
The CRF Center for Education trains practitioners in advanced techniques and innovations at more than 50 educational meetings and conferences each year, including the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

CRF is a 501(c)3 nonprofit organization.

close
0.30941